Last updated on February 2018

Pilot Study of FFP104 Dose Escalation in PBC Subjects

Brief description of study

The purpose of this study is to determine the initial safety, tolerability and pharmacodynamics of the CD40-antagonist Mab, FFP104, in subjects with PBC

Clinical Study Identifier: NCT02193360

Find a site near you

Start Over